Journal
MITOCHONDRION
Volume 20, Issue -, Pages 34-42Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.mito.2014.10.006
Keywords
GDF15; Pyruvate; Mitochondrial diseases; Cybrid; Microarray; Biomarker
Categories
Funding
- Ministry of Education, Culture, Sports, Science, and Technology of Japan
- GMEXT/JSPS [A-25242062, A-22240072, B-21390459, C-26670481, C-21590411, CER-24650414, C-26350922, C-25461571, YSB-25860891]
- Ministry of Health, Labor, and Welfare of Japan
- Takeda Science Foundation
- [23-Nanchi-Ippan-016]
- [23-Nanchi-Ippan-116]
- [24-Nanchi-Ippan-005]
- Grants-in-Aid for Scientific Research [25242062, 26350922, 26670342, 21590411, 25461571, 26670481, 25860891] Funding Source: KAKEN
Ask authors/readers for more resources
Pyruvate therapy is a promising approach for the treatment of mitochondrial diseases. To identify novel biomarkers for diagnosis and to evaluate therapeutic efficacy, we performed microarray analysis of 2SD cybrid cells harboring a MELAS-causing mutation and control cells treated with either lactate or pyruvate. We found that expression and secretion of growth differentiation factor 15 (GDF15) were increased in 2SD cells treated with lactate and that serum GDF15 levels were significantly higher in patients with mitochondrial diseases than in those with other diseases, suggesting that GDF15 could be a useful marker for diagnosis and evaluating the therapeutic efficacy of pyruvate. (C) 2014 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available